eFFECTOR Therapeutics (EFTRW) Stock Analysis

What eFFECTOR Therapeutics does

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Key metrics

ETFs linked to EFTRW

Broad-market and Healthcare sector ETFs an investor holding eFFECTOR Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EFTRW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for eFFECTOR Therapeutics?

eFFECTOR Therapeutics trades under the ticker EFTRW on NASDAQ.

Which exchange is EFTRW listed on?

EFTRW is listed on NASDAQ.

What sector does eFFECTOR Therapeutics operate in?

eFFECTOR Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EFTRW in a portfolio?

PortView shows EFTRW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.